8 results on '"Walet, Sylvia"'
Search Results
2. Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines
- Author
-
Calvo-Lerma, Joaquim, Hulst, Jessie M., Asseiceira, Inês, Claes, Ine, Garriga, Maria, Colombo, Carla, Fornés, Victoria, Woodcock, Sandra, Martins, Tiago, Boon, Mieke, Ruperto, Mar, Walet, Sylvia, Speziali, Chiara, Witters, Peter, Masip, Etna, Barreto, Celeste, de Boeck, Kris, and Ribes-Koninckx, Carmen
- Published
- 2017
- Full Text
- View/download PDF
3. Study Protocol of the Exercise Study: Unraveling Limitations for Physical Activity in Children With Chronic Diseases Order to Target Them With Tailored Interventions—A Randomized Cross Over Trial
- Author
-
Scheffers, Linda E., primary, Helbing, Willem A., additional, Utens, Elisabeth M. W. J., additional, Dieleman, Gwen C., additional, Dulfer, Karolijn, additional, Noske, Josefien, additional, van den Broek, Eline A., additional, Walet, Sylvia, additional, Olieman, Joanne F., additional, Escher, Johanna C., additional, Pijnenburg, Marielle W., additional, van der Ploeg, Ans T., additional, and van den Berg, Linda E., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Clinical evaluation of an evidence-based method based on food characteristics to adjust pancreatic enzyme supplements dose in cystic fibrosis
- Author
-
Universitat Politècnica de València. Departamento de Tecnología de Alimentos - Departament de Tecnologia d'Aliments, Unión Europea, Calvo-Lerma, Joaquim, Boon, Mieke, Colombo, Carla, de Koning, Barbara, Asseiceira, Ines, Garriga, Maria, Roca, María, Claes, Ine, Bulfamante, Anna, Walet, Sylvia, Pereira, Luisa, Ruperto, Mar, Masip, Etna, Asensio-Grau, Andrea, Giana, Arianna, Affourtit, Philine, Heredia Gutiérrez, Ana Belén, Vicente, Saioa, Andrés Grau, Ana María, De Boeck, Kris, Hulst, Jessie, Ribes-Koninckx, Carmen, Universitat Politècnica de València. Departamento de Tecnología de Alimentos - Departament de Tecnologia d'Aliments, Unión Europea, Calvo-Lerma, Joaquim, Boon, Mieke, Colombo, Carla, de Koning, Barbara, Asseiceira, Ines, Garriga, Maria, Roca, María, Claes, Ine, Bulfamante, Anna, Walet, Sylvia, Pereira, Luisa, Ruperto, Mar, Masip, Etna, Asensio-Grau, Andrea, Giana, Arianna, Affourtit, Philine, Heredia Gutiérrez, Ana Belén, Vicente, Saioa, Andrés Grau, Ana María, De Boeck, Kris, Hulst, Jessie, and Ribes-Koninckx, Carmen
- Abstract
[EN] Background: Patients with cystic fibrosis (CF) and pancreatic insufficiency need pancreatic enzyme replacement therapy (PERT) for dietary lipids digestion. There is limited evidence for recommending the adequate PERT dose for every meal, and controlling steatorrhea remains a challenge. This study aimed to evaluate a new PERT dosing method supported by a self-management mobile-app. Methods: Children with CF recruited from 6 European centres were instructed to use the app, including an algorithm for optimal PERT dosing based on in vitro digestion studies for every type of food. At base-line, a 24h self-selected diet was registered in the app, and usual PERT doses were taken by the patient. After 1 month, the same diet was followed, but PERT doses were indicated by the app. Change in faecal fat and coefficient of fat absorption (CFA) were determined. Results: 58 patients (median age 8.1 years) participated. Baseline fat absorption was high: median CFA 96.9%, median 2.4g faecal fat). After intervention CFA did not significantly change, but range of PERT doses was reduced: interquartile ranges narrowing from 1447-3070 at baseline to 1783-2495 LU/g fat when using the app. Patients with a low baseline fat absorption (CFA<90%, n= 12) experienced significant improvement in CFA after adhering to the recommended PERT dose (from 86.3 to 94.0%, p=0.031). Conclusion: the use of a novel evidence-based PERT dosing method, based on in vitro fat digestion studies incorporating food characteristics, was effective in increasing CFA in patients with poor baseline fat absorption and could safely be implemented in clinical practice.
- Published
- 2021
5. Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis
- Author
-
Calvo-Lerma, J, Hulst, Jessie, Boon, Martijn, Colombo, C, Masip, E, Ruperto, M, Fornes-Ferrer, V, Kooij, Els, Claes, I, Garriga, M, Roca, M, Crespo-Escobar, P, Bulfamante, A, Woodcock, S, Martinez-Barona, S, Andres, A, de Boeck, K, Ribes-Koninckx, C, Asensio-Grau, A, Asseiceira, I, Barreto, C, Martinez, AC, Heredia, A, Martins, T, Nobili, R, Pereira, L, Paz-Yepez, C, Valmarana, L, Valmarana, R, Walet, Sylvia, Pediatrics, Otorhinolaryngology and Head and Neck Surgery, and Erasmus MC other
- Subjects
Male ,Cystic Fibrosis ,Pulmonology ,Physiology ,PH ,Cell Membranes ,Pilot Projects ,CHILDREN ,Biochemistry ,Cystic fibrosis ,Body Mass Index ,Fats ,Feces ,0302 clinical medicine ,Medicine and Health Sciences ,Pert ,Medicine ,Prospective Studies ,Child ,Prospective cohort study ,Meal ,Evidence-Based Medicine ,Multidisciplinary ,Pharmaceutics ,Age Factors ,Regression analysis ,Enzyme replacement therapy ,Proton Pumps ,Lipids ,3. Good health ,Multidisciplinary Sciences ,Phenotype ,Genetic Diseases ,Regression Analysis ,Engineering and Technology ,Science & Technology - Other Topics ,Female ,Digestion ,030211 gastroenterology & hepatology ,Cellular Structures and Organelles ,COEFFICIENT ,Management Engineering ,Research Article ,medicine.medical_specialty ,Adolescent ,Science ,03 medical and health sciences ,Sex Factors ,Dose Prediction Methods ,Autosomal Recessive Diseases ,Internal medicine ,Humans ,Enzyme Replacement Therapy ,Management Planning and Control ,Dosing ,Pancreas ,Nutrition ,Clinical Genetics ,Science & Technology ,business.industry ,Biology and Life Sciences ,Membrane Proteins ,Lipase ,Cell Biology ,IN-VITRO ,Evidence-based medicine ,medicine.disease ,Dietary Fats ,Fibrosis ,Diet ,030228 respiratory system ,Food ,Physiological Processes ,business ,Body mass index ,Developmental Biology - Abstract
BACKGROUND: A method to adjust Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis is not currently available. OBJECTIVES: To assess the in vivo efficacy of a method to adjust the dose of enzymatic supplement in CF extrapolated from previous in vitro digestion studies (theoretical optimal dose, TOD). Secondly, to assess how individual patient characteristics influence the expected coefficient of fat absorption (CFA) and thus to identify an individual correction factor to improve TOD. METHODS: A prospective interventional study in 43 paediatric patients with CF from 5 European centres. They followed a 24h fixed diet with the theoretical optimal dose for each meal. Faecal collection was carried out between colorimetric markers in order to include all the faeces corresponding to the fixed diet. Beta regression models were applied to assess the associations of individual patient characteristics with the CFA. RESULTS: Median CFA was 90% (84, 94% 1st, 3rd Q.) with no significant differences among centres. Intestinal transit time was positively associated with CFA (p = 0.007), but no statistical associations were found with and age, gender, phenotype or BMI. Regression model showed no improvement of the in vitro predicted theoretical optimal dose when taking individual patient characteristics into account. CONCLUSION: Strict adherence to the theoretical optimal dose of enzymatic supplement for a prescribed meal, led to median CFA levels at the clinical target of 90% with a low variability between patients. The proposed method can be considered as a first approach for an evidence-based method in PERT dosing based on food characteristics. Results have to be confirmed in free dietary settings. ispartof: PLOS ONE vol:14 issue:3 ispartof: location:United States status: published
- Published
- 2019
6. Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents
- Author
-
Boon, M, Claes, I, Havermans, T, Fornés-Ferrer, V, Calvo-Lerma, J, Asseiceira, I, Bulfamante, A, Garriga, M, Masip, E, Woodcock, S, Walet, Sylvia, Barreto, C, Colombo, C, Crespo, P, Kooij, Els, Hulst, Jessie, Martinez-Barona, S, Nobili, R, Pereira, L, Ruperto, M, Vicente, S, de Boeck, K, Ribes-Koninckx, C, Boon, M, Claes, I, Havermans, T, Fornés-Ferrer, V, Calvo-Lerma, J, Asseiceira, I, Bulfamante, A, Garriga, M, Masip, E, Woodcock, S, Walet, Sylvia, Barreto, C, Colombo, C, Crespo, P, Kooij, Els, Hulst, Jessie, Martinez-Barona, S, Nobili, R, Pereira, L, Ruperto, M, Vicente, S, de Boeck, K, and Ribes-Koninckx, C
- Published
- 2019
7. Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents.
- Author
-
Boon, Mieke, Claes, Ine, Havermans, Trudy, Fornés-Ferrer, Victoria, Calvo-Lerma, Joaquim, Asseiceira, Inês, Bulfamante, Anna, Garriga, María, Masip, Etna, Woodcock, Sandra, Walet, Sylvia, Barreto, Celeste, Colombo, Carla, Crespo, Paula, Van der Wiel, Els, Hulst, Jessie, Martinez-Barona, Sandra, Nobili, Rita, Pereira, Luisa, and Ruperto, Mar
- Subjects
CYSTIC fibrosis ,QUALITY of life ,PARENTS ,EXOCRINE pancreatic insufficiency ,MOBILE apps ,WORKING parents ,CRONBACH'S alpha - Abstract
Background: Most patients with cystic fibrosis (CF) suffer from pancreatic insufficiency, leading to fat malabsorption, malnutrition and abdominal discomfort. Until recently, no specific tool was available for assessing gastro-intestinal related quality of life (GI QOL) in patients with CF. As the Horizon2020 project MyCyFAPP aims to improve GI QOL by using a newly designed mobile application, a sensitive and reliable outcome measure was needed. We aimed to study the applicability of the existing child-specific Pediatric Quality of Life Inventory, Gastrointestinal Symptoms Scales and Module (PedsQL GI) in children with CF. Methods: A multicenter, prospective observational study was performed in 6 European centers to validate the PedsQL GI in children with CF during 3 months. Results: In total, 248 children and their parents were included. Within-patient variability of PedsQL GI was low (24.11), and there was reasonable agreement between children and parents (ICC 0.681). Nine of 14 subscales were informative (no ceiling effect). The PedsQL GI and the median scores for 4 subscales were significantly lower in patients compared to healthy controls. Positive associations were found between PedsQL GI and age (OR = 1.044, p = 0.004) and between PedsQL GI and BMI z-score (OR = 1.127, p = 0.036). PedsQL GI correlated with most CFQ-R subscales (r 0.268 to 0.623) and with a Visual Analogue Scale (r = 0.20). Conclusions: PedsQL GI is a valid and applicable instrument to assess GI QOL in children with CF. Future research efforts should examine the responsiveness of the CF PedsQL GI to change in the context of clinical interventions and trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Study Protocol of the Exercise Study: Unraveling Limitations for Physical Activity in Children With Chronic Diseases in Order to Target Them With Tailored Interventions-A Randomized Cross Over Trial.
- Author
-
Scheffers LE, Helbing WA, Utens EMWJ, Dieleman GC, Dulfer K, Noske J, van den Broek EA, Walet S, Olieman JF, Escher JC, Pijnenburg MW, van der Ploeg AT, and van den Berg LE
- Abstract
Introduction: Physical activity is associated with many physiological and psychological health benefits across the lifespan. Children with a chronic disease often have lower levels of daily physical activity, and a decreased exercise capacity compared to healthy peers. In order to learn more about limitations for physical activity, we investigate children with four different chronic diseases: children with a Fontan circulation, children with Broncho Pulmonary Dysplasia (BPD), Pompe disease and inflammatory bowel disease (IBD). Each of these diseases is likely to interfere with physical activity in a different way. Knowing the specific limitations for physical activity would make it possible to target these, and increase physical activity by a personalized intervention. The aim of this study is to first investigate limitations for physical activity in children with various chronic diseases. Secondly, to measure the effects of a tailored exercise intervention, possibly including a personalized dietary advice and/or psychological counseling, on exercise capacity, endurance, quality of life, fatigue, fear for exercise, safety, muscle strength, physical activity levels, energy balance, and body composition. Methods and Analysis: This randomized crossover trial will aim to include 72 children, aged 6-18 years, with one of the following diagnosis: a Fontan circulation, BPD, Pompe disease and IBD. Eligible patients will participate in the 12-week tailored exercise intervention and are either randomized to start with a control period or start with the intervention. The tailored 12-week exercise interventions, possibly including a personalized dietary advice and/or psychological counseling, will be designed based on the found limitations for physical activity in each disease group during baseline measurements by the Rotterdam Exercise Team. Effects of the tailored training interventions will be measured on the following endpoints: exercise capacity (measured by cardiopulmonary exercise test), endurance, physical activity levels, muscle strength, quality of life, fatigue, fear for exercise, disease activity, cardiac function (in children with a Fontan circulation), energy balance, and body composition. Ethics and Dissemination: Conducted according to the Declaration of Helsinki and Good Clinical Practice. Medical-ethical approval was obtained. Trial Registration Number: NL8181, https://www.trialregister.nl/trial/8181., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Scheffers, Helbing, Utens, Dieleman, Dulfer, Noske, van den Broek, Walet, Olieman, Escher, Pijnenburg, van der Ploeg and van den Berg.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.